PHOENIX — Eplontersen monotherapy without baseline transthyretin stabilizers preserved the health status of patients with transthyretin amyloidosis with cardiomyopathy out to 140 weeks, a speaker reported.The results of a post hoc analysis of the CARDIO-TTRansform trial of eplont
